Recommendations from the U.S. Preventive Services Task Force (USPSTF) shouldn’t be tied to insurance coverage, according to the physicians who helped craft those guidelines.

Rep. Chris Stewart, R-Utah, is circulating a letter among members of his party calling for a lawsuit against HHS to block the agency from settling legal disputes with insurers over the Affordable Care Act’s risk corridor program.

Warnings for specific prescription drugs may not cover the implications of mixing certain medications, which can mean side effects much worse than just dizziness or upset stomach. While many of the dangerous drug parings have been discovered, many are still hidden. Researchers from New York's Columbia University Medical Center and the Data Science Institute at Columbia University are using data science to uncover such interactions.

Technology company CureVac has appointed Pierre Kemula as new chief financial officer, a position responsible for overseeing the company’s financial and capital market initiatives.

Unfriendly malpractice laws and a high cost-of-living are driving physicians away from Connecticut, according to State Rep. Prasad Srinivasin. And he should know, since he’s a physician himself.

Rather than use prescription drug monitoring programs (PDMPs) only to track opioid prescriptions, two physicians writing in the American Journal of Managed Care suggested the concept be expanded to collect and report information on all prescriptions.

Healthcare groups including HIMSS, AMIA and CHIME have written a letter to members of Congress asking for a national patient identifier to increase patient safety and the electronic exchange of data.

Mylan, the manufacturer of EpiPen, will pay $465 million to the federal government to “resolve questions” about whether the autoinjector was misclassified as a generic drug, therefore reducing the quarterly rebates Mylan owed.